Drug Profile

TILT 234

Alternative Names: Ad3-hTERT-CMV-hCD40L

Latest Information Update: 28 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator TILT Biotherapeutics
Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
Mechanism of Action Cell death stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

No development reported Solid tumours

Most Recent Events

28 Nov 2025 No recent reports of development identified for preclinical development in Solid-tumours in Finland (IV)
30 Nov 2023 TILT 234 is still in preclinical development for Solid tumours in Finland (TILT Biotherapeutics pipeline, November 2023)
26 Oct 2023 TILT 234 is available for licensing as of 26 Oct 2023. https://tiltbio.com/pipeline/

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com